Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06483334 | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Feb 18, 2026 | clinicaltrials |
| NCT05239143 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 180 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2026 |
| clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT02473536 | Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC | active not recruiting | Phase 1 / Phase 2 | 25 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06234605 | A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 80 | HiberCell, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies(PRISM) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT02989584 | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT05030506 | A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | active not recruiting | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04863885 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | active not recruiting | Phase 1 / Phase 2 | 46 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04989959 | [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 35 | Orhan Kemal OzOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05768347 | Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC | active not recruiting | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06132945 | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | active not recruiting | Phase 1 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02420847 | Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 / Phase 2 | 57 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03589339 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | active not recruiting | Phase 1 | 145 | NanobiotixINDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04163289 | Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation(PERFORM) | active not recruiting | Phase 1 | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06848868 | Ambulatory Flexible URS for UTUC Surveillance | recruiting | Phase 1 | 10 | Chinese University of Hong KongOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06351904 | A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy | recruiting | Phase 1 | 72 | Ractigen Therapeutics.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 390 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 90 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06181266 | A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer(PARADIGM-1) | active not recruiting | Phase 1 | 22 | Prokarium LtdINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT07122414 | A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 80 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07097935 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 104 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04522323 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 | 67 | MedImmune LLCINDUSTRY | 4 | Jul 25, 2025 | clinicaltrials |
| NCT07064863 | A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.(BCG-TIME) | not yet recruiting | Phase 1 / Phase 2 | 31 | Queen's UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2026source: clinicaltrials